Cherilyn Murer to Chair Buck Advisory Council

Chicago-based consultant and lawyer is an active voice in the advancement of quality and cost-effective healthcare

Novato, CA, June 15, 2016:  Cherilyn G. Murer has been appointed as Chairman of the Buck Advisory Council (BAC), a prestigious group of men and women from the United States and around the world dedicated to helping advance the Buck Institute’s scientific and educational mission aimed at extending the healthy years of life.

     Murer is the CEO of the Murer Group, a Chicago-based national consultancy which assists large, multi-hospital healthcare systems, academic medical centers and large physician group practices navigate through the complex regulatory, strategic and financial issues facing healthcare today. She received her law degree from Northern Illinois University and was Director of Rehabilitation Medicine at Northwestern Memorial Hospital in Chicago prior to starting her own company.

     In keeping with her commitment to health policy and reform, Murer joined the Buck Institute Board of Trustees in 2015. She assumes the Chairmanship of the BAC on July 1. “It is an honor to lead a group focused on ensuring the success of the Buck - a pioneering institute whose efforts impact all of us,” she said. “We need to address both the challenges and opportunities presented by an aging population and the Buck is poised to play a major role in efforts to extend the healthy years of life.”  

     In addition to her service at the Buck Institute, Murer is a Trustee of the Lebanese American University where she chairs the Governance Committee and serves on the Health Services and Finance Committees. She is also serving a second six-year term as a Trustee of Northern Illinois University, an appointment made by Illinois Governor Pat Quinn and approved by the State Senate. Additionally, she holds an appointment to the faculty of the University of Illinois at Chicago College of Medicine as a Clinical Assistant Professor of Law in the Department of Family Medicine. Murer has authored or co-authored seven books aimed at helping healthcare administrators deal with issues related to case management, complex compliance issues and strategic planning for creating effective integrated health systems.

     “Cherilyn Murer’s background, expertise and passion to advance quality, cost-effective healthcare make her a perfect match for both our Board and the BAC,” said Brian Kennedy, PhD, Buck Institute President and CEO.  “The BAC plays a major role in advancing our mission and I am thrilled that she has accepted a leadership role in the organization. I look forward to working with her as we strive to make the Buck as successful as possible.”

About the Buck Advisory Council (BAC)

The BAC comprises a diverse group of individuals from the United States and around the world. Members include leaders in government, business, finance, pharmaceuticals, law and other fields of endeavor. Many have served as advisors to governments, public commissions and nonprofit commissions. These leaders provide advice on strategic priorities, serve as ambassadors to raise the visibility of Institute achievements, and set the pace for philanthropy at the Institute. The BAC meets twice each year:  in the San Francisco Bay Area each spring and in a foreign destination each fall. At these meetings, members participate in panel discussions with faculty and other experts and develop ideas to promote the Buck Institute globally as a leader in research on aging and age-related disease. 

About the Buck Institute for Research on Aging:

The Buck Institute is the U.S.’s first independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. 

Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.  In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information:

Change text size: